Establishment Labs (NASDAQ:ESTA – Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Establishment Labs to post earnings of ($0.22) per share and revenue of $63.7980 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.
Establishment Labs Stock Performance
Shares of Establishment Labs stock opened at $74.60 on Tuesday. The firm has a market cap of $2.17 billion, a PE ratio of -26.27 and a beta of 0.99. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $78.24. The business’s fifty day simple moving average is $70.55 and its 200-day simple moving average is $56.20.
Hedge Funds Weigh In On Establishment Labs
Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares in the last quarter. Swiss National Bank increased its holdings in Establishment Labs by 1.8% during the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after purchasing an additional 600 shares during the period. Kestra Advisory Services LLC acquired a new stake in Establishment Labs in the 4th quarter valued at about $47,000. Private Advisor Group LLC boosted its stake in shares of Establishment Labs by 14.1% in the 3rd quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after buying an additional 675 shares during the period. Finally, Quarry LP purchased a new position in shares of Establishment Labs in the 3rd quarter valued at about $34,000. Institutional investors and hedge funds own 72.91% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Establishment Labs
Establishment Labs Company Profile
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Recommended Stories
- Five stocks we like better than Establishment Labs
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
